Hi,
Our 108th issue of Gems brings with some of the exciting updates in the field of diabetes care. The U.S. FDA has approved Novo Nordisk’s fast-acting insulin Fiasp to treat diabetes. With its many improved features over conventional fast-acting insulins, Fiasp more closely resembles the natural physiological insulin response to meals.
The opening article in the current Gems issue is regarding a clinical trial that has revealed the benefits of a fully automated Artificial Pancreas system in improving glycemic control and lessening the hypoglycemic events in T1D adolescents during prolonged intensive winter sports activities, despite the added challenges of cold and altitude.
Other articles that find place in this issue include- Follow-up results from the LEADER trial revealing the benefits of liraglutide (Victoza) in preventing kidney disease in type 2 diabetes patients, A sex-specific study from Aarhus University in Denmark that points out the risk of a man developing diabetes if his spouse is obese, Latest evidences that point towards the association between high sodium intake and increased risk of developing type 2 diabetes, and Latest research from the Duke-NUS Medical School in Singapore indicating that a person's risk of diabetes gets increased by high consumption of red meat and poultry.
Our regular updates- Gems picture of the month, Recipe of the month, JDC updates and Drug updates continue.
Thanking you once again for the comments and suggestions. If in case you are not interested in receiving this free monthly scientific newsletter, kindly reply with "delete gems" in the subject line to info@jothydev.net and also click the unsubscribe button at the bottom of this page.
Regards
JDC Diabetes Gems Team
Jothydev's Diabetes and Research Centres
Trivandrum and Kochi, Kerala, INDIA
+91 9846040055, +91 9746366655
http://www.jothydev.net
